InMed Pharmaceuticals Inc. (NASDAQ:INM) Q2 2022 Earnings Conference Call February 15, 2022 2:00 PM ET
Corporate Participants
Colin Clancy - Senior Director of Investor Relations
Eric Adams - President and Chief Executive Officer
Bruce Colwill - Chief Financial Officer
Eric Hsu - Senior Vice President, Preclinical Research and Development
Alexandra Mancini - Senior Vice President, Clinical and Regulatory Affairs
Shane Johnson - Senior Vice President and General Manager of BayMedica
Conference Call Participants
Mitchell Kapoor - HC Wainwright
Scott Henry - ROTH Capital Partners
Ken Mestemacher - Edison Group
Operator
Good morning. My name is Shannon, and I will be your conference operator today. At this time, I would like to welcome everyone to InMed's Second Quarter Fiscal 2022 Financial Results and Business Update Conference Call for the period ended December 31, 2021. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions]. Thank you.
Mr. Clancy, you may begin your conference.
Colin Clancy
Thank you, Shannon, and good day, ladies and gentlemen. My name is Colin Clancy, InMed's Senior Director of Investor Relations. Welcome to InMed’s second quarter fiscal 2022 financial results and business update conference call. Please note our speakers are joining us today from remote locations, so we appreciate your patience if we encounter any unexpected technical challenges.
Before we begin, we would like to go over our disclosure statements, followed by an update in our health and wellness commercial activities together with the progress update on our pharmaceutical drug development programs which will be led by our President and CEO, Eric Adams. Mr. Bruce Colwill, our Chief Financial Officer will then review the financial results of operations. Following that, we will be available for a question-and-answer session.
Also joining us today to
- Read more current INM analysis and news
- View all earnings call transcripts